Tatiana Hernández

Delfos Hospital — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index273citations18works25.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related gene regulation(5), Cancer Immunotherapy and Biomarkers(2), Lung Cancer Treatments and Mutations(2), CAR-T cell therapy research(2), Cancer therapeutics and mechanisms(2)

Publications18 total

1307 ICT01, a γ9δ2 T-cell-activating mAb, in combination with pembrolizumab elicits deep and durable responses in second-line patients with primary refractory melanoma: Results from EVICTION study
2025Open Access
Abstract PS7-02: First-in-human results of STX-478, a mutant-selective PI3K alpha inhibitor, in HR+ breast cancer and advanced solid tumor patients
Clinical Cancer Research·2025· 1 cited
692 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with refractory melanoma: interim results from study EVICTION
Regular and Young Investigator Award Abstracts·2024Open Access
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study
Marine Drugs·2024· 4 citedOpen Access
MYC targeting by OMO-103 in solid tumors: a phase 1 trial
Nature Medicine·2024· 147 citedOpen Access
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study
Pharmaceuticals·2024· 1 citedOpen Access
Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Tables 1-3 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Data from Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
2023Open Access
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
Clinical Cancer Research·2023· 65 cited
A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science Translational Medicine·2023· 55 cited

Frequent Co-authors

Víctor Moreno(13), Bernard Doger(13), Vladimir Galvao(12), María Vieito(11), Anna Spreafico(11), Irene Braña(11), Judy S. Wang(11), Meir Preis(11), Sofia Genta(11), Aaron R. Hansen(11), Laurie Lenox(11), Regina J. Brown(11), Anna Kalota(11), Jaydeep Mehta(11), Friederike Pastore(11), Bharvin Patel(11), Pankaj Mistry(11), Junchen Gu(11), Josh Lauring(11), Manish R. Patel(11)